84 related articles for article (PubMed ID: 24594997)
1. Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma.
Saroufim A; Messai Y; Hasmim M; Rioux N; Iacovelli R; Verhoest G; Bensalah K; Patard JJ; Albiges L; Azzarone B; Escudier B; Chouaib S
Br J Cancer; 2014 Apr; 110(7):1778-84. PubMed ID: 24594997
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of a panel of two biomarkers (E-cadherin and CD105) in laryngeal cancer.
Zvrko E; Vuckovic L; Radunovic M
Pol J Pathol; 2023; 74(4):225-231. PubMed ID: 38477084
[TBL] [Abstract][Full Text] [Related]
3. Isolation and characterization of renal cancer stem cells from patient-derived xenografts.
Hasmim M; Bruno S; Azzi S; Gallerne C; Michel JG; Chiabotto G; Lecoz V; Romei C; Spaggiari GM; Pezzolo A; Pistoia V; Angevin E; Gad S; Ferlicot S; Messai Y; Kieda C; Clay D; Sabatini F; Escudier B; Camussi G; Eid P; Azzarone B; Chouaib S
Oncotarget; 2016 Mar; 7(13):15507-24. PubMed ID: 26551931
[TBL] [Abstract][Full Text] [Related]
4. Enzalutamide in European and North American men participating in the AFFIRM trial.
Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Shariftabrizi A; Rasti A; Asgari M
Cancer Biomark; 2018; 21(4):821-837. PubMed ID: 29286924
[TBL] [Abstract][Full Text] [Related]
6. Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes.
Zhuo H; Zheng B; Liu J; Huang Y; Wang H; Zheng D; Mao N; Meng J; Zhou S; Zhong L; Zhao Y
J Exp Clin Cancer Res; 2018 Mar; 37(1):42. PubMed ID: 29499713
[TBL] [Abstract][Full Text] [Related]
7.
Ding YD; Shu LZ; He RS; Chen KY; Deng YJ; Zhou ZB; Xiong Y; Deng H
Front Immunol; 2023; 14():1278011. PubMed ID: 37868979
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma.
Sharma R; Balta S; Raza A; Escalona RM; Kannourakis G; Prithviraj P; Ahmed N
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174052
[TBL] [Abstract][Full Text] [Related]
9. Tumoral CD105 promotes immunosuppression, metastasis, and angiogenesis in renal cell carcinoma.
Oladejo M; Nguyen HM; Seah H; Datta A; Wood LM
Cancer Immunol Immunother; 2023 Jun; 72(6):1633-1646. PubMed ID: 36586013
[TBL] [Abstract][Full Text] [Related]
10. The Mutually Mediated Chloride Intracellular Channel Protein 1 (CLIC1) Relationship between Malignant Cells and Tumor Blood Vessel Endothelium Exhibits a Significant Impact on Tumor Angiogenesis, Progression, and Metastasis in Clear Cell Renal Cell Carcinoma (ccRCC).
Ferician AM; Ferician OC; Nesiu A; Cosma AA; Caplar BD; Melnic E; Cimpean AM
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497464
[TBL] [Abstract][Full Text] [Related]
11. Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma.
Oladejo M; Nguyen HM; Silwal A; Reese B; Paulishak W; Markiewski MM; Wood LM
Front Immunol; 2022; 13():1038807. PubMed ID: 36439126
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study.
Chrabańska M; Rynkiewicz M; Kiczmer P; Drozdzowska B
J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079127
[TBL] [Abstract][Full Text] [Related]
13. Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy.
Virumbrales-Muñoz M; Ayuso JM; Loken JR; Denecke KM; Rehman S; Skala MC; Abel EJ; Beebe DJ
Biomaterials; 2022 Apr; 283():121454. PubMed ID: 35299086
[TBL] [Abstract][Full Text] [Related]
14. CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target.
Li L; Zhong L; Tang C; Gan L; Mo T; Na J; He J; Huang Y
Clin Transl Oncol; 2022 Aug; 24(8):1447-1458. PubMed ID: 35165838
[TBL] [Abstract][Full Text] [Related]
15. Renal tumor biomarkers (Review).
Bratu O; Mischianu D; Marcu D; Spinu D; Iorga L; Cherciu A; Balescu I; Bacalbasa N; Diaconu C; Savu C; Savu C; Anghel R
Exp Ther Med; 2021 Nov; 22(5):1297. PubMed ID: 34630652
[TBL] [Abstract][Full Text] [Related]
16. Heterogenous expression of endoglin marks advanced renal cancer with distinct tumor microenvironment fitness.
Momoi Y; Nishida J; Miyakuni K; Kuroda M; Kubota SI; Miyazono K; Ehata S
Cancer Sci; 2021 Aug; 112(8):3136-3149. PubMed ID: 34091990
[TBL] [Abstract][Full Text] [Related]
17. Identification of a foetal epigenetic compartment in adult human kidney.
Wiencke JK; Zhang Z; Koestler DC; Salas LA; Molinaro AM; Christensen BC; Kelsey KT
Epigenetics; 2022 Mar; 17(3):335-355. PubMed ID: 33783321
[TBL] [Abstract][Full Text] [Related]
18. Expressions of TWIST1 and CD105 markers in colorectal cancer patients and their association with metastatic potential and prognosis.
Fattahi F; Saeednejad Zanjani L; Vafaei S; Habibi Shams Z; Kiani J; Naseri M; Gheytanchi E; Madjd Z
Diagn Pathol; 2021 Mar; 16(1):26. PubMed ID: 33752711
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
